Cervomed reports first quarter 2025 financial results and provides corporate updates

Reported positive 16-week results from the extension phase of the phase 2b rewind-lb trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with lewy bodies (dlb)
CRVO Ratings Summary
CRVO Quant Ranking